SAN FRANCISCO -- For selected patients with mitral regurgitation (MR), the Sapien M3 device delivered highly promising 1-year outcomes for the desperate field of transcatheter mitral valve replacement ...
One-year outcomes in the ENCIRCLE trial’s main cohort (299 patients unsuitable for other treatment options) achieved low rates for death and low heart failure hospitalization for patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results